You are here

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

sandy craine's picture
Submitted by sandy craine on Sun, 05/02/2012 - 12:41pm

 

Abstract
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still evaluated using prognostic scores developed in the chemotherapy and interferon era.

 

Abstract
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still evaluated using prognostic scores developed in the chemotherapy and interferon era.

Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

sandy craine's picture
Submitted by sandy craine on Mon, 30/01/2012 - 4:46pm

Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.  Jorge Cortes, January 2012

Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.  Jorge Cortes, January 2012

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors: David Marin et al

sandy craine's picture
Submitted by sandy craine on Wed, 25/01/2012 - 2:39pm

Purpose:

We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) and other outcomes more reliably than serial marrow cytogenetics.

Purpose:

We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) and other outcomes more reliably than serial marrow cytogenetics.

Chronic Myeloid Leukemia 2010:Where Are We Now and Where Can We Go? Jerald P. Radich

sandy craine's picture
Submitted by sandy craine on Tue, 24/01/2012 - 12:33am

Chronic myeloid leukemia is a model of how the molecular understanding of a disease can provide the platform for therapy and diagnostics. Clinicians are now empowered with first- and second-generation tyrosine kinases, as well as molecular tools to monitor disease and characterize resistance. However, there are still unanswered questions regarding optimization of therapy, the utility of molecular monitoring, and the search (or need) of “cure” that bears thought. In this review, we will discuss these issues, as they provide a roadmap for what may lie ahead in the therapy of other hematologic malignancies, particular the other myeloproliferative syndromes, where specific genetic lesions, and targeted therapy, are now being realized.

Chronic myeloid leukemia is a model of how the molecular understanding of a disease can provide the platform for therapy and diagnostics. Clinicians are now empowered with first- and second-generation tyrosine kinases, as well as molecular tools to monitor disease and characterize resistance. However, there are still unanswered questions regarding optimization of therapy, the utility of molecular monitoring, and the search (or need) of “cure” that bears thought. In this review, we will discuss these issues, as they provide a roadmap for what may lie ahead in the therapy of other hematologic malignancies, particular the other myeloproliferative syndromes, where specific genetic lesions, and targeted therapy, are now being realized.

Poor response to second-line kinase inhibitors in CML patients with multiple low-level mutations, irrespective of their resistance profile

sandy craine's picture
Submitted by sandy craine on Sun, 22/01/2012 - 2:31pm
Wendy T Parker, Musei Ho, Hamish S Scott, Timothy P Hughes, Susan Branford.

Wendy T Parker, Musei Ho, Hamish S Scott, Timothy P Hughes, Susan Branford.

CML Support Group: Response to the Appeal Panel Judgement

sandy craine's picture
Submitted by sandy craine on Mon, 16/01/2012 - 1:43pm

CML Support Group: Response to the Appeal Panel judgement in favour of the NICE 

decision not to recommend dasatinib as a second line treatment option for imatinib

resistant CML and in patients intolerant to imatinib, and including its use in blast

phase CML.

CML Support Group: Response to the Appeal Panel judgement in favour of the NICE 

decision not to recommend dasatinib as a second line treatment option for imatinib

resistant CML and in patients intolerant to imatinib, and including its use in blast

phase CML.

NICE say NO to dasatinib and high dose IM. Full Guidance

sandy craine's picture
Submitted by sandy craine on Sun, 15/01/2012 - 12:49pm

 

Guidance: Patient version
Dasatinib, high-dose imatinib and nilotinib for chronic myeloid leukaemia:
This document is about when dasatinib, high-dose imatinib and 
nilotinib should be used to treat people with chronic myeloid leukaemia
that has not responded to imatinib or who cannot tolerate imatinib in the 
NHS in England and Wales. It explains guidance (advice) from NICE 

 

Guidance: Patient version

Dasatinib, high-dose imatinib and nilotinib for chronic myeloid leukaemia:

This document is about when dasatinib, high-dose imatinib and 

nilotinib should be used to treat people with chronic myeloid leukaemia

that has not responded to imatinib or who cannot tolerate imatinib in the 

NHS in England and Wales. It explains guidance (advice) from NICE 

Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure? Junia V. Melo1 and David M. Ross2

sandy craine's picture
Submitted by sandy craine on Fri, 13/01/2012 - 3:12pm

 

Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure? 

 

Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure? 

CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley OncologySTAT Editorial Team. Nov 23 2010

sandy craine's picture
Submitted by sandy craine on Tue, 10/01/2012 - 8:14pm

CML—The Changing Landscape of Front-line Therapy:

Interview With Dr. Jane Apperley

CML—The Changing Landscape of Front-line Therapy:

Interview With Dr. Jane Apperley

Pages